MGMT promoter methylation, tumor

Alphabetical Test listing

MGMT promoter methylation, tumor-Pathology add-on

  
MGMT promoter methylation, tumor
  
Pathology add-on
  

Prognostication of newly diagnosed glioblastomas Identifying newly diagnosed glioblastomas that may respond to alkylating chemotherapy (ie, temozolomide) Guiding therapy decision making for newly diagnosed glioblastomas in elderly patients (>60 years)

  
Tissue
  

At least 40% tumor is required for this assay. In general, a 6 mm x 3 mm area of tissue cut at 5 micron thickness is the minimum amount of tissue needed; this could be collected over multiple slides.

  

Submit processed tissue block

  

Formalin-fixed, paraffin-embedded (FFPE) tissue block

  

One (1) slide stained with hematoxylin and eosin and five (5) unstained, non-baked 5-micron thick sections of the tumor

  

Ambient (preferred)

Frozen

Refrigerated

  
Mayo Clinic Laboratories (MGMT): R
  
Weekly; varies
  
7 - 10 days
  

Methylation-specific Polymerase Chain Reaction (PCR) analysis

  

An interpretive report will be provided.

  
81287 - slide review
88381
  
Yes
  
  
06/15/2018
  
11/14/2018